Forward Pharma A Stock Probability Of Bankruptcy
| FWPDelisted Stock | USD 2.56 0.00 0.00% |
Forward |
Forward Pharma A Company probability of distress Analysis
Forward Pharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Forward Pharma Probability Of Bankruptcy | Over 100% |
Most of Forward Pharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Forward Pharma A is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Forward Pharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Forward Pharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Forward Pharma A financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Forward Pharma A has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the Biotechnology sector and 82.35% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Forward Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Forward Pharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Forward Pharma could also be used in its relative valuation, which is a method of valuing Forward Pharma by comparing valuation metrics of similar companies.Forward Pharma is currently under evaluation in probability of bankruptcy category among its peers.
Forward Fundamentals
| Return On Equity | -0.0083 | |||
| Return On Asset | -0.0342 | |||
| Current Valuation | (43.04 M) | |||
| Shares Outstanding | 7.09 M | |||
| Shares Owned By Institutions | 12.90 % | |||
| Number Of Shares Shorted | 4.51 K | |||
| Price To Earning | 0.13 X | |||
| Price To Book | 0.31 X | |||
| EBITDA | (1.89 M) | |||
| Net Income | (1.89 M) | |||
| Cash And Equivalents | 70.77 M | |||
| Cash Per Share | 10.08 X | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 117.44 X | |||
| Book Value Per Share | 8.76 X | |||
| Cash Flow From Operations | (2.36 M) | |||
| Short Ratio | 1.78 X | |||
| Earnings Per Share | (0.27) X | |||
| Price To Earnings To Growth | 0.13 X | |||
| Target Price | 37.0 | |||
| Beta | 1.38 | |||
| Market Capitalization | 13.83 M | |||
| Total Asset | 71.41 M | |||
| Retained Earnings | (9.1 M) | |||
| Working Capital | 93.59 M | |||
| Current Asset | 99.8 M | |||
| Current Liabilities | 6.21 M | |||
| Z Score | 1.2 | |||
| Net Asset | 71.41 M |
About Forward Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Forward Pharma A's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Forward Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Forward Pharma A based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Forward Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Forward Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Forward Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Forward Stock
| 0.57 | MMM | 3M Company Fiscal Year End 28th of January 2025 | PairCorr |
| 0.56 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
| 0.52 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.49 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.36 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
The ability to find closely correlated positions to Forward Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Forward Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Forward Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Forward Pharma A to buy it.
The correlation of Forward Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Forward Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Forward Pharma A moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Forward Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Forward Stock
If you are still planning to invest in Forward Pharma A check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Forward Pharma's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |